Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.

The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of solid tumours is now increasing. Cutaneous side effects, namely acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, hair and nail changes, are reported in literature. We describe a case of a man treated with an EGFR-inhibitor (erlotinib) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution.